Combined inhibition of CDK4/6 and AKT is effective in Rb-intact triple-negative breast cancer of the luminal androgen receptor (LAR) subtype

被引：0
|
作者：
Kim, Gun Min
Lee, Kyung-min
Sudhan, Dhivya
Lin, Albert
Marin, Arnaldo
Chatterjee, Sumanta
Ye, Dan
Kandagatla, Vishal
Mendiratta, Saurabh
Hanker, Ariella
Arteaga, Carlos
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-PD3-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD3-07
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
    Xiuzhi Zhu
    Li Chen
    Binhao Huang
    Xiaoguang Li
    Liu Yang
    Xin Hu
    Yizhou Jiang
    Zhimin Shao
    Zhonghua Wang
    Journal of Experimental & Clinical Cancer Research, 40
  • [32] Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition
    Demirsoy, Seyma
    Tran, Ha
    Liu, Joseph
    Li, Yunzhan
    Yang, Shengyu
    Aregawi, Dawit
    Glantz, Michael J.
    Jacob, Naduparambil K.
    Walter, Vonn
    Schell, Todd D.
    Olmez, Inan
    CANCERS, 2024, 16 (12)
  • [33] Digital spatial profiling of immune-related proteins in luminal androgen receptor (LAR) vs non-LAR triple-negative breast cancer (TNBC)
    Leon-Ferre, Roberto A.
    Carter, Jodi M.
    Zahrieh, David M.
    Hillman, David W.
    Chumsri, Saranya
    Ma, Yaohua
    Kachergus, Jennifer M.
    Wang, Xue
    Boughey, Judy C.
    Liu, Minetta C.
    Ingle, James N.
    Kalari, Krishna R.
    Bisneto, Jose C. Villasboas
    Couch, Fergus J.
    Thompson, E. Aubrey
    Goetz, Matthew P.
    CANCER RESEARCH, 2022, 82 (04)
  • [34] Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
    Lee, Miseon
    Yoo, Tae-Kyung
    Chae, Byung Joo
    Lee, Ahwon
    Cha, Yoon Jin
    Lee, Jieun
    Ahn, Sung Gwe
    Kang, Jun
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [35] Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition.
    Asghar, Uzma
    Herrera-Abreu, Maria Teresa
    Cutts, Ros
    Babina, Irina
    Pearson, Alex
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
    Meiou Dai
    Chenjing Zhang
    Ayad Ali
    Xinyuan Hong
    Jun Tian
    Chieh Lo
    Nadège Fils-Aimé
    Sergio A. Burgos
    Suhad Ali
    Jean-Jacques Lebrun
    Scientific Reports, 6
  • [37] CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
    Dai, Meiou
    Zhang, Chenjing
    Ali, Ayad
    Hong, Xinyuan
    Tian, Jun
    Lo, Chieh
    Fils-Aime, Nadege
    Burgos, Sergio A.
    Ali, Suhad
    Lebrun, Jean-Jacques
    SCIENTIFIC REPORTS, 2016, 6
  • [38] Combined inhibition of CDK2 and CDK4/6 overcomes acquired resistance to CDK4/6 inhibitors in breast cancer via RB-independent pathway
    Pandey, Kamal
    CANCER RESEARCH, 2020, 80 (16)
  • [39] Differential metabolic response of triple-negative and estrogen receptor-positive breast cancer cells to abemaciclib, a CDK4/6 inhibitor
    Jiang, Jun
    Bao, Xun
    Jiang, Yuanyuan
    Yue, Yang
    Huettemann, Maik
    Li, Jing
    CANCER RESEARCH, 2024, 84 (06)
  • [40] Investigating anti-tumor immunity with CDK4/6 inhibition in triple negative breast cancer.
    Guo, Qiuchen
    Spasic, Milos
    Goreczny, Gregory
    Maynard, Adam
    McAllister, Sandra
    CANCER RESEARCH, 2021, 81 (13)
12345